Richard Kuntz - 01 Jun 2025 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role
Director
Signature
/s/ Scott Kellen, attorney-in-fact
Issuer symbol
DMAC
Transactions as of
01 Jun 2025
Transactions value $
$0
Form type
4
Filing time
03 Jun 2025, 16:16:41 UTC
Previous filing
09 May 2025
Next filing
02 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kuntz Richard Director 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS /s/ Scott Kellen, attorney-in-fact 03 Jun 2025 0001341125

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding DMAC Voting Common Shares, no par value per share 24,210 01 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMAC Stock Option (right to buy) Award $0 +32,162 $0.000000 32,162 01 Jun 2025 Common Shares 32,162 $4.11 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 7,443 shares issuable on vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan.
F2 Vests in four nearly equal quarterly installments over one year.